2099.5000 -33.00 (-1.55%)
NSE Sep 15, 2025 15:31 PM
Volume: 546.8K
 

2099.50
-1.55%
HDFC Securities
Glenmarks strong top line performance (16% YoY) and sequential improvement in profitability led to 24% YoY earnings growth in 1QFY17. Revenues increased to Rs 18.8bn with US business growing at 24% YoY.
Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.
More from Glenmark Pharmaceuticals Ltd.
Recommended